Cannabis
Khiron Welcomes Legalization of Medical Cannabis in Brazil
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, welcomes today’s announcement from ANVISA, the National Agency for Health Surveillance of Brazil, establishing a legalized environment for the sale and consumption of cannabis for medical use. The new regulations will be published in the coming days on the Federal Official Gazette and enter into law 90 days after that.
In the announcement from ANVISA, a new class of medical cannabis-based products will be prescribed by doctors and sold through pharmacies, enabling patient safe and legal access. The regulatory framework sets a comprehensive procedure for the manufacture and import of these products as well as the requirements for commercialization, prescription, dispensing, monitoring and supervision of cannabis products for medical purposes. The resolution was approved unanimously and is valid for an initial three-year term.
Andres Galofre, Khiron Co-founder and Vice President, Business Development, commented, “We congratulate legislators and the health authority in Brazil for their leadership in establishing a legalized environment for medical cannabis in the country. With a population of over 200 million this will directly benefit the health and wellbeing of a significant number of patients in Brazil and affirms our position as a LatAm leader in a rapidly globalizing cannabis market.”
Khiron has a firmly established market-entry strategy for Brazil, with Dormul S.A., its wholly owned subsidiary based in Uruguay giving the Company access to the Brazilian market through the Mercosur Regional Trading Bloc. The Company has initiated pre-clinical medical cannabis studies with the Universidad de la República of Uruguay and Institut Pasteur de Montevideo, providing direct strategic opportunity for 3 million patients for medical cannabis in Uruguay, and a Brazilian market of 3.4 million (New Frontier Data). Further, on November 29th the Company announced it had received authorization from the Colombian Technical Quotas Group (“TQG”) for the commercialization of medical use High THC cannabis for domestic and export purposes, including to Brazil, with manufacture to begin in Q1 2020.
SOURCE Khiron Life Sciences Corp.
-
Avant2 weeks ago
Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
-
StickIt1 week ago
StickIt Technologies Inc. Announces Year-End 2023 Financial Results
-
Cannabis1 week ago
Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology
-
Cannabis1 week ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis1 week ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis1 week ago
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Cannabis1 week ago
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
-
Cannabis1 week ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services